Heart Failure patients

  • Akiyama et al, JACC, Journal of American College
    of  Cardiology, 2012

    • Method: 321 patients with heart failure  tested  with EndoPAT®. Rate of adverse events was almost
      4 times in the group of endothelial dysfunction (28.1%) vs.  8.8% in the normal function group.
      Patients followed up for a mean of 20 months
    • Unique EndoPAT® value: Peripheral endothelial dysfunction independently correlated with future
      cardiovascular events, adding incremental clinical significance for risk stratification in patients with HF.